United Therapeutics Corporation (NASDAQ:UTHR) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday.

Other equities research analysts have also issued reports about the stock. BidaskClub raised shares of United Therapeutics Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 16th. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. UBS AG reissued a “sell” rating and issued a $106.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Oppenheimer Holdings Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. Six research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $134.50.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 122.82 on Monday. The stock’s 50 day moving average price is $125.12 and its 200 day moving average price is $127.11. The company has a market cap of $5.34 billion, a PE ratio of 14.24 and a beta of 1.50. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The business had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 EPS. Equities analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-rating-increased-to-buy-at-valuengine/1606449.html.

In other news, CEO Martine A. Rothblatt sold 2,176 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $127.11, for a total transaction of $276,591.36. Following the completion of the transaction, the chief executive officer now directly owns 3,245 shares in the company, valued at $412,471.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 590 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the transaction, the director now directly owns 3,875 shares in the company, valued at $513,863.75. The disclosure for this sale can be found here. Insiders sold 18,286 shares of company stock valued at $2,338,602 over the last 90 days. 7.80% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. State of Wisconsin Investment Board bought a new stake in shares of United Therapeutics Corporation in the 2nd quarter valued at $5,256,000. Comerica Bank lifted its holdings in United Therapeutics Corporation by 1.3% in the second quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock valued at $4,635,000 after buying an additional 458 shares during the period. JPMorgan Chase & Co. lifted its holdings in United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares during the period. River & Mercantile Asset Management LLP acquired a new position in United Therapeutics Corporation in the second quarter valued at $908,000. Finally, Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation in the first quarter valued at $230,000.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.